FGFR4 is a Prognostic Marker and Therapeutic Target for Ovarian Cancer

Posted on January 25, 2013

Research

In the journal Clinical Cancer Research, a group of researchers, including current and past OCRF grantees Anil Sood and Gabriel Lopez-Berestein, evaluated the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer.

They found that FGFR4 is a prognostic marker for the disease. Furthermore, silencing FGFR4 significantly decreases ovarian tumor growth. These findings suggest that targeting those ovarian cancer cells with high levels of FGFR4 is a new therapeutic target, and may improve patient survival.

Read the abstract here.

Related Topics

OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies

OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies

A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued

OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs

OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs

Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued

OCRA-Funded Research Expands Impact of DNA and RNA Data

OCRA-Funded Research Expands Impact of DNA and RNA Data

A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.